Carvolix

Carvolix EBITDA per Share

The EBITDA per Share of Carvolix (CVX.PA) as of Nov 3, 2026 is -0.46 EUR. In the previous year, EBITDA per Share was -0.34 EUR — a change of 33.84% (lower).

EBITDA per Share

-0.46EUR

YoY

33.84%

Last updated:

EBITDA per Share of Carvolix is 2025 -0.46 EUR. EBITDA per Share of Carvolix was 2024 -0.34 EUR. It decreases by 33.84% lower compared to the previous year.

The Carvolix EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
-0.82 EUR
Jan 1, 2019
-0.70 EUR
Jan 1, 2020
-0.73 EUR
Jan 1, 2021
-0.53 EUR
Jan 1, 2022
-0.60 EUR
Jan 1, 2023
-0.42 EUR
Jan 1, 2024
-0.34 EUR
Jan 1, 2025
-0.46 EUR
The Carvolix EBITDA per Share history
YEAREBITDA per ShareYoY
-0.46EUR+33.84%
-0.34EUR-18.60%
-0.42EUR-30.27%
-0.60EUR+14.07%
-0.53EUR-28.11%
-0.73EUR+4.60%
-0.70EUR-14.52%
-0.82EUR+46.29%
-0.56EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carvolix Stock analysis

What does Carvolix do? Affluent Medical SA develops minimally invasive prostheses that mimic human anatomy and restore native physiology for cardiovascular and urological therapies. The company offers products including Kalios, Epygon, and Artus, targeting heart disease and urinary incontinence treatments. These solutions utilize transcatheter and flow control technologies with optimized, biocompatible components designed for minimally invasive implant procedures. The company's products are sold to healthcare providers and medical institutions seeking advanced solutions for critical conditions. Affluent Medical SA focuses on treating serious and widespread diseases through innovative implantable technologies that replicate natural bodily functions without extensive surgical intervention. With a workforce of 54 full-time employees based in Aix-En-Provence, Paca, the company delivers specialized medical devices that address unmet needs in cardiovascular and urological care. Its product portfolio targets high-value clinical segments where minimally invasive approaches improve patient outcomes and reduce recovery times. Carvolix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Carvolix stock

EBITDA per Share of Carvolix is -0.46 EUR in 2025.

EBITDA per Share of Carvolix changed from -0.34 EUR to -0.46 EUR, representing a 33.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Carvolix since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Carvolix

All Key Metrics — Carvolix